ID

23465

Descrição

Study of Enzastaurin Versus Placebo With Pemetrexed for Patients With Advanced or Metastatic Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00530621

Link

https://clinicaltrials.gov/show/NCT00530621

Palavras-chave

  1. 06/07/2017 06/07/2017 -
Transferido a

6 de julho de 2017

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Non-small Cell Lung Cancer NCT00530621

Eligibility Non-small Cell Lung Cancer NCT00530621

Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
laboratory confirmed diagnosis of nsclc with locally advanced or metastatic disease which cannot be cured.
Descrição

ID.1

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0278987
patients must have disease which progressed after 1 prior systemic cytotoxic chemotherapy regimen for advanced disease.
Descrição

ID.2

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0278940
at least 1 measurable lesion.
Descrição

ID.3

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0221198
must have stopped all previous systemic therapies for cancer for at least 2 weeks prior to enrollment.
Descrição

ID.4

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0444930
must be able to follow study guidelines and be able to show up for appointments.
Descrição

ID.5

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1321605
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Descrição

ID.6

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0013230
previous treatment with enzastaurin or pemetrexed.
Descrição

ID.7

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1327830
UMLS CUI [1,2]
C0210657
concurrent administration of any other antitumor therapy.
Descrição

ID.8

Tipo de dados

boolean

Alias
UMLS CUI [1]
C2986475
inability to swallow tablets
Descrição

ID.9

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0566357
UMLS CUI [1,2]
C0039225
pregnant or breastfeeding
Descrição

ID.10

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147

Similar models

Eligibility Non-small Cell Lung Cancer NCT00530621

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
laboratory confirmed diagnosis of nsclc with locally advanced or metastatic disease which cannot be cured.
boolean
C0007131 (UMLS CUI [1,1])
C0278987 (UMLS CUI [1,2])
ID.2
Item
patients must have disease which progressed after 1 prior systemic cytotoxic chemotherapy regimen for advanced disease.
boolean
C0278940 (UMLS CUI [1])
ID.3
Item
at least 1 measurable lesion.
boolean
C0221198 (UMLS CUI [1])
ID.4
Item
must have stopped all previous systemic therapies for cancer for at least 2 weeks prior to enrollment.
boolean
C0087111 (UMLS CUI [1,1])
C0444930 (UMLS CUI [1,2])
ID.5
Item
must be able to follow study guidelines and be able to show up for appointments.
boolean
C1321605 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
ID.6
Item
treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
boolean
C0013230 (UMLS CUI [1])
ID.7
Item
previous treatment with enzastaurin or pemetrexed.
boolean
C1327830 (UMLS CUI [1,1])
C0210657 (UMLS CUI [1,2])
ID.8
Item
concurrent administration of any other antitumor therapy.
boolean
C2986475 (UMLS CUI [1])
ID.9
Item
inability to swallow tablets
boolean
C0566357 (UMLS CUI [1,1])
C0039225 (UMLS CUI [1,2])
ID.10
Item
pregnant or breastfeeding
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial